Purpose: to assess the utility of response monitoring to enzalutamide by using [Ga]Ga-PSMA PET in mCRPC patients treated with enzalutamide as first-line therapy.
Methods: patients underwent [Ga]Ga-PSMA PET less than 8 weeks before and 3 months after starting enzalutamide. On the basis of EAU/EANM criteria, patients were categorized as PSMA responders (PET-R) or PSMA non-responders (PET-NR), whilst, based on PSA, they were classified as biochemical responders (PSA-R) or non-responders (PSA-NR). Survival analysis was performed using the Cox regression hazard model and the Kaplan-Meier method.
Results: 69 patients were considered fully evaluable. We observed 47.8% of concordance between [68Ga]Ga-PSMA PET and PSA monitoring at 3 months after starting enzalutamide. For discordant cases, the PSA reduction has a weak impact on PFS and a significant impact on OS in PET-NR patients, whilst this change has no impact either for PFS and OS in PET-R ones.
Conclusions: [Ga]Ga-PSMA PET could be a useful imaging tool for monitoring response to enzalutamide in mCRPC patients, being more informative than PSA in this setting, and possibly better guiding clinicians in therapeutic decisions.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11599341 | PMC |
| http://dx.doi.org/10.1007/s00259-024-06887-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Imply on diagnosis and early prognosis of preoperative [Ga]Ga-PSMA-11 PET/CT in patients with suspected brain tumours of glial origin.
Sci Rep
January 2025
Nuclear Medicine Department, Medical University of Warsaw, Banacha 1a, 02-097, Warsaw, Poland.
PET/CT targeting prostate-specific membrane antigen (PSMA) is commonly used in patients with prostate cancer. PSMA has been found in other solid tumours, including primary brain tumours. The aim of this study was to evaluate the usefulness of [Ga]Ga-PSMA-11 PET/CT for preoperative diagnosis and 2-year prognosis.
View Article and Find Full Text PDFA comparison of routine [Ga]Ga-PSMA-11 preparation using Locametz and Illuccix kits.
EJNMMI Radiopharm Chem
December 2024
Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, MI, 48109, USA.
Background: Approval of Locametz and Illuccix kits for the manufacture of [Ga]Ga-PSMA-11 (gallium Ga68 gozetotide), a PET imaging agent for prostate cancer, as well as the corresponding therapeutic ([Lu]Lu-PSMA-617 Pluvicto), has led to a rapid increase in demand for [Ga]Ga-PSMA-11 PET imaging. Radiopharmaceutical manufacturers, using Ge/Ga generators, may decide to adopt Locametz and/or Illuccix kits, which requires a comparison to select the most suitable kit for day-to-day use. The objective of this article is to compare both kits and provide guidance for selecting one for routine use, as well as evaluate labeling consistency of both kits during routine production.
View Article and Find Full Text PDFThe Challenge of External Generalisability: Insights from the Bicentric Validation of a [Ga]Ga-PSMA-11 PET Based Radiomics Signature for Primary Prostate Cancer Characterisation Using Histopathology as Reference.
Cancers (Basel)
December 2024
Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, 20132 Milan, Italy.
: PSMA PET radiomics is a promising tool for primary prostate cancer (PCa) characterisation. However, small single-centre studies and lack of external validation hinder definitive conclusions on the potential of PSMA PET radiomics in the initial workup of PCa. We aimed to validate a radiomics signature in a larger internal cohort and in an external cohort from a separate centre.
View Article and Find Full Text PDFPreoperative detection of extraprostatic tumor extension in patients with primary prostate cancer utilizing [Ga]Ga-PSMA-11 PET/MRI.
Insights Imaging
December 2024
Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria.
Article Synopsis
- Radical prostatectomy (RP) is a standard treatment for localized prostate cancer, but accurately detecting extraprostatic extension (EPE) before surgery is difficult, which can lead to suboptimal treatments.
- This study explores using explainable machine learning to improve EPE detection by analyzing data from newly diagnosed prostate cancer patients who underwent PET/MRI imaging and subsequent surgery.
- The results showed machine learning models outperformed traditional imaging methods in predicting EPE, which could lead to better clinical decision-making and improved patient outcomes.
Development of a homotrimeric PSMA radioligand based on the NOTI chelating platform.
EJNMMI Radiopharm Chem
December 2024
Department of Nuclear Medicine, Saarland University - Medical Center, Kirrbergerstrasse, 66421, Homburg, Germany.
Background: The NOTI chelating scaffold can readily be derivatized for bioconjugation without impacting its metal complexation/radiolabeling properties making it an attractive building block for the development of multimeric/-valent radiopharmaceuticals. The objective of the study was to further explore the potential of the NOTI chelating platform by preparing and characterizing homotrimeric PSMA radioconjugates in order to identify a suitable candidate for clinical translation.
Results: Altogether, three PSMA conjugates based on the NOTI-TVA scaffold with different spacer entities between the chelating unit and the Glu-CO-Lys PSMA binding motif were readily prepared by solid phase-peptide chemistry.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!